When it comes to the top biotech stocks to consider buying this month, as identified in today’s article, one has a virtual monopoly in its market and lots of cash. Another doesn’t have a monopoly, doesn’t have lots of cash, and doesn’t even have an approved drug on the market yet! What this small biotech does have, however, “is tremendous growth potential and at least one possible game-changer in its pipeline” – and while it’s the riskiest of the three stocks, it could also be the biggest winner. For more, CLICK HERE.
What is the best possible stock or exchange-traded fund to buy right now (if by “best” we mean the stock or ETF likely to produce the highest risk-adjusted return)? The author of today’s article believes that he has the answer to that question – a momentum strategy play. To find out what the stock or fund in question is – and for the author’s recommendations on when and how to buy – CLICK HERE.